OR WAIT null SECS
With a cost of approximately $514 million, expected completion is 2026
Lonza, a contract development and manufacturing organization serving the pharma, biotech and nutrition sectors, will be building a large-scale commercial drug product fill-finish facility in Stein, Switzerland, the same campus as the company’s current clinical drug product center.
The financial commitment allows the company to provide customers with an end-to-end solution that includes commercial drug product manufacturing for large-scale market supply. The CDMO will be investing approximately $514 million and is expected to be completed by 2026.
“As Lonza continues to build its end-to-end offering into drug product manufacturing, we bring customers integrated offers that will increase speed to market, flexibility, and simplicity, in line with our strategy,” says Jean-Christophe Hyvert, president, biologics and cell & gene, Lonza. “Building on our experience and expertise in addressing drug product development, formulation, and manufacturing challenges, this new facility will enable us to capture additional market share and fulfill sustained customer demand for commercial drug product manufacturing.”